Clinical Trials Logo

Lymphoma, B-Cell, Marginal Zone clinical trials

View clinical trials related to Lymphoma, B-Cell, Marginal Zone.

Filter by:

NCT ID: NCT04043845 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Start date: February 3, 2020
Phase: Phase 1
Study type: Interventional

This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).

NCT ID: NCT03999697 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Start date: December 1, 2018
Phase: Phase 1
Study type: Interventional

Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)

NCT ID: NCT03919175 Terminated - Lymphoma Clinical Trials

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.

NCT ID: NCT03846427 Completed - Clinical trials for Marginal Zone Lymphoma

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

MAGNOLIA
Start date: February 19, 2019
Phase: Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

NCT ID: NCT03797456 Completed - MZL Clinical Trials

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 110 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

NCT ID: NCT03768505 Terminated - Clinical trials for Non Hodgkin Lymphoma

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Start date: June 25, 2019
Phase: Phase 2
Study type: Interventional

This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy

NCT ID: NCT03740529 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Start date: November 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

NCT ID: NCT03697512 Active, not recruiting - Clinical trials for Splenic Marginal Zone Lymphoma

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

MALIBU
Start date: September 27, 2019
Phase: Phase 2
Study type: Interventional

Single-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma (EMZL). It is planned to recruit 130 patients. Additional patients with Splenic Marginal Zone Lymphoma (SMZL), up to 30, and Nodal Marginal Zone Lymphoma (NMZL), up to 15, will be included in the trial in order to preliminary explore the clinical activity and safety of the combination treatment proposed. The study primary endpoints will be analysed on the EMZL population. Outcome of patients with SMZL and NMZL will be analysed and reported separately

NCT ID: NCT03680586 Active, not recruiting - Clinical trials for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma

Start date: February 4, 2019
Phase: Early Phase 1
Study type: Interventional

This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphoma. Ultra low-dose radiation therapy may be able to kill tumor cells and shrink tumors while having fewer side effects in patients with MALT lymphoma.

NCT ID: NCT03646422 Recruiting - Lymphoma, B-Cell Clinical Trials

AEDV Registry of Primary Cutaneous Lymphoma

Start date: September 1, 2016
Phase:
Study type: Observational [Patient Registry]

Registry of patients with Primary Cutaneous Lymphoma seen at participating centers in Spain. The registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies.